Cancer Immunology, Immunotherapy

, Volume 51, Issue 10, pp 532–538

Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients

  • Nathalie Labarrière
  • Marie-Christine Pandolfino
  • Nadine Gervois
  • Amir Khammari
  • Marie-Hélène Tessier
  • Brigitte Dréno
  • Francine Jotereau
Original Article

DOI: 10.1007/s00262-002-0313-3

Cite this article as:
Labarrière, N., Pandolfino, M., Gervois, N. et al. Cancer Immunol Immunother (2002) 51: 532. doi:10.1007/s00262-002-0313-3

Abstract.

Adoptive therapy for cancer using tumor-infiltrating lymphocytes (TIL) has mainly been investigated in cancer patients with advanced stage disease. The limited clinical success has not been encouraging, although this might be explained by poor TIL specificity and/or high tumor burden. To re-evaluate the effectiveness of adoptive therapy, we analyzed the capacity of tumor-reactive TIL injection in preventing the further development of disease in stage III melanoma patients after complete tumor resection. A phase II/III randomized trial was performed on 88 melanoma patients, who received autologous TIL plus interleukin-2 (IL-2) or IL-2 only. The duration of relapse-free survival was analyzed, taking into account the immunological specificity of injected TIL and the number of metastatic lymph nodes removed before treatment. Kaplan-Meyer analysis revealed that the injection of tumor-reactive TIL was statistically correlated with prolonged relapse-free survival in patients with only one metastatic lymph node. Therefore, improved clinical outcome could be obtained after adoptive therapy by selecting appropriate groups of patients and monitoring the specificity of the injected TIL populations.

Adoptive therapy IFN-γ Melanoma TIL T lymphocyte

Copyright information

© Springer-Verlag 2002

Authors and Affiliations

  • Nathalie Labarrière
    • 1
  • Marie-Christine Pandolfino
    • 2
  • Nadine Gervois
    • 1
  • Amir Khammari
    • 4
  • Marie-Hélène Tessier
    • 4
  • Brigitte Dréno
    • 1
  • Francine Jotereau
    • 1
  1. 1.Unité INSERM U463, 9 Quai Moncousu, 44093 Nantes Cedex 1, France
  2. 2.Unité de Thérapie Cellulaire et Génétique, CHRU de Nantes, 9 Quai Moncousu, 44093 Nantes, France
  3. 3.Faculté des Sciences de Nantes, 2, rue de la Houssinière, BP 92208, 44322 Nantes Cedex France
  4. 4.Skin Cancer Unit, CHU de Nantes, 1 Allée de l'Ile Gloriette, 44093 Nantes, France